
AUTL
Autolus Therapeutics PLC
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.585
Open
2.550
VWAP
--
Vol
1.01M
Mkt Cap
670.68M
Low
2.530
Amount
--
EV/EBITDA(TTM)
--
Total Shares
266.04M
EV
407.54M
EV/OCF(TTM)
--
P/S(TTM)
74.42
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
1.98M
-80.39%
-0.223
+147.57%
--
--
-0.233
-24.81%
--
--
-0.235
+6.76%
Estimates Revision
The market is revising Upward the revenue expectations for Autolus Therapeutics plc (AUTL) for FY2025, with the revenue forecasts being adjusted by 60.26% over the past three months. During the same period, the stock price has changed by 84.53%.
Revenue Estimates for FY2025
Revise Upward

+60.26%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-2.71%
In Past 3 Month
Stock Price
Go Up

+84.53%
In Past 3 Month
3 Analyst Rating

289.86% Upside
Wall Street analysts forecast AUTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AUTL is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy

289.86% Upside
Current: 2.565

Low
10.00
Averages
10.00
High
10.00

289.86% Upside
Current: 2.565

Low
10.00
Averages
10.00
High
10.00
Needham
Gil Blum
Strong Buy
Reiterates
$10
2025-04-10
Reason
Needham
Gil Blum
Price Target
$10
2025-04-10
Reiterates
Strong Buy
Reason
Truist Securities
Asthika Goonewardene
Strong Buy
Maintains
$11 → $10
2025-04-01
Reason
Truist Securities
Asthika Goonewardene
Price Target
$11 → $10
2025-04-01
Maintains
Strong Buy
Reason
Truist lowered the firm's price target on Autolus Therapeutics to $10 from $11 and keeps a Buy rating on the shares. The firm is updating its model and estimates for Autolus, slightly lowering our price target as it removes AUTO4 from its valuation, the analyst tells investors in a research note. Truist adds it is assigning no value to autoimmune indications, but this could change following Autolus' April R&D day.
Wells Fargo
Yanan Zhu
Buy
Maintains
$8 → $6
2025-03-21
Reason
Wells Fargo
Yanan Zhu
Price Target
$8 → $6
2025-03-21
Maintains
Buy
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$10
2025-01-13
Reason
Needham
Gil Blum
Price Target
$10
2025-01-13
Reiterates
Strong Buy
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$10
2024-12-09
Reason
Needham
Gil Blum
Price Target
$10
2024-12-09
Reiterates
Strong Buy
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$10
2024-12-05
Reason
Needham
Gil Blum
Price Target
$10
2024-12-05
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Autolus Therapeutics PLC (AUTL.O) is -2.72, compared to its 5-year average forward P/E of -3.26. For a more detailed relative valuation and DCF analysis to assess Autolus Therapeutics PLC 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-3.26
Current PE
-2.72
Overvalued PE
-1.57
Undervalued PE
-4.96
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-2.24
Current EV/EBITDA
-2.11
Overvalued EV/EBITDA
-0.53
Undervalued EV/EBITDA
-3.96
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
172.10
Current PS
10.14
Overvalued PS
364.17
Undervalued PS
-19.97
Financials
Annual
Quarterly
FY2025Q1
YoY :
-10.99%
8.98M
Total Revenue
FY2025Q1
YoY :
+68.32%
-65.24M
Operating Profit
FY2025Q1
YoY :
+33.16%
-70.16M
Net Income after Tax
FY2025Q1
YoY :
+8.33%
-0.26
EPS - Diluted
FY2025Q1
YoY :
+104.18%
-83.81M
Free Cash Flow
FY2025Q1
YoY :
-199.86%
-99.86
Gross Profit Margin - %
FY2025Q1
YoY :
+118.14%
-3.15K
FCF Margin - %
FY2025Q1
YoY :
+49.60%
-781.13
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
4.1M
Volume
4
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
3.6M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
AUTL News & Events
Events Timeline
2025-07-21 (ET)
2025-07-21
07:02:58
Autolus announces EC granted marketing authorization for AUCATZYL

2025-05-23 (ET)
2025-05-23
08:31:36
Autolus Therapeutics announces positive CHMP opinion for obe-cel

2025-05-14 (ET)
2025-05-14
09:38:17
Autolus Therapeutics presents clinical data updates at EHA Congress

Sign Up For More Events
Sign Up For More Events
News
9.0
07-21NewsfilterAutolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
9.0
06-30BenzingaFDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
9.0
06-24PRnewswireWall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
Sign Up For More News
People Also Watch

FARO
FARO Technologies Inc
44.000
USD
+0.48%

LDI
loanDepot Inc
1.685
USD
-5.34%

ACIC
American Coastal Insurance Corp
10.380
USD
-2.35%

GRAL
Grail Inc
38.170
USD
-5.26%

RERE
ATRenew Inc
3.305
USD
-2.79%

IRWD
Ironwood Pharmaceuticals Inc
0.802
USD
-1.84%

UPB
Upstream Bio Inc
14.310
USD
+4.99%

CMP
Compass Minerals International Inc
20.320
USD
-0.25%

ZJK
ZJK Industrial Co Ltd
3.360
USD
-6.15%

KODK
Eastman Kodak Co
6.835
USD
+0.51%
FAQ

What is Autolus Therapeutics PLC (AUTL) stock price today?
The current price of AUTL is 2.565 USD — it has increased 1.79 % in the last trading day.

What is Autolus Therapeutics PLC (AUTL)'s business?

What is the price predicton of AUTL Stock?

What is Autolus Therapeutics PLC (AUTL)'s revenue for the last quarter?

What is Autolus Therapeutics PLC (AUTL)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Autolus Therapeutics PLC (AUTL)'s fundamentals?

How many employees does Autolus Therapeutics PLC (AUTL). have?
